| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
α-Amyrin targets multiple pathways. It inhibits HIV-1 reverse transcriptase with an IC50 of 3.3 µM. It activates the ERK and GSK-3β signaling pathways. The compound inhibits the proliferation of B16 2F2 melanoma cells and LPS-induced nitric oxide (NO) production in RAW 264.7 macrophages.
|
|---|---|
| ln Vitro |
In vitro, α-Amyrin inhibits HIV-1 reverse transcriptase (IC50 = 3.3 µM). It inhibits the proliferation of B16 2F2 melanoma cells. It also inhibits LPS-induced nitric oxide (NO) production in RAW 264.7 macrophages. The compound shows anti-bacterial and anti-inflammatory activity.
|
| ln Vivo |
In vivo, α-Amyrin can reduce blood glucose levels. It has been shown to offer protective effects on dopaminergic neurons by reducing 6-hydroxydopamine (6-OHDA)-induced cell damage. The compound exhibits strong antioxidant activity, reducing intracellular ROS.
|
| Enzyme Assay |
The in vitro enzyme assay for α-Amyrin involves measuring its inhibition of HIV-1 reverse transcriptase. The enzyme is incubated with a template-primer and nucleotides in the presence of varying compound concentrations. The IC50 of 3.3 µM is determined by quantifying the reduction in DNA synthesis.
|
| Cell Assay |
Cellular assays for α-Amyrin are performed using RAW 264.7 macrophages. Cells are stimulated with LPS to induce nitric oxide (NO) production in the presence of varying concentrations of the compound. NO levels are measured using the Griess assay.
|
| Animal Protocol |
In vivo animal studies for α-Amyrin are conducted in models of neurodegenerative disease. The compound has been shown to offer protective effects on dopaminergic neurons in a 6-OHDA model. Specific dosing regimens are not detailed in the available sources.
|
| ADME/Pharmacokinetics |
α-Amyrin is an orally active compound. It has a molecular weight of 426.72 g/mol. Specific PK parameters such as half-life, bioavailability, and clearance are not detailed in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicity data for α-Amyrin are not reported in the available sources. As a naturally occurring compound, it is generally considered to have a favorable safety profile. Specific toxicological studies have not been described.
|
| References |
|
| Additional Infomation |
δ-Amyrinol is a pentacyclic triterpenoid compound belonging to the oleanane type. It has a double bond between positions 13 and 18, and the hydrogen at the 3β position is replaced by a hydroxyl group. It is a pentacyclic triterpenoid and also a secondary alcohol. δ-Amyrinol is derived from the hydride of oleanane. It has been reported to exist in plants of the genus Euphorbia supina, Gymnosporia montana, and other organisms with relevant data.
α-Amyrin is a natural pentacyclic triterpenoid with diverse biological activities. It shows anti-bacterial, anti-inflammatory, and anti-cancer properties. The compound activates ERK and GSK-3β signaling and can reduce blood glucose levels. It is available from commercial suppliers for research purposes. |
| Molecular Formula |
C30H50O
|
|---|---|
| Molecular Weight |
426.7174
|
| Exact Mass |
426.386
|
| CAS # |
508-04-3
|
| PubChem CID |
12358447
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
491.2±44.0 °C at 760 mmHg
|
| Flash Point |
217.8±20.7 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
11.09
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
31
|
| Complexity |
803
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@@]12CC[C@@]3(C(=C1CC(CC2)(C)C)CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)C
|
| InChi Key |
JOCIRBSYAYKMEF-YDPPSCFKSA-N
|
| InChi Code |
InChI=1S/C30H50O/c1-25(2)15-16-27(5)17-18-29(7)20(21(27)19-25)9-10-23-28(6)13-12-24(31)26(3,4)22(28)11-14-30(23,29)8/h22-24,31H,9-19H2,1-8H3/t22-,23+,24-,27+,28-,29+,30+/m0/s1
|
| Chemical Name |
(3S,4aR,6aR,6bS,8aR,14aR,14bR)-4,4,6a,6b,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3435 mL | 11.7173 mL | 23.4346 mL | |
| 5 mM | 0.4687 mL | 2.3435 mL | 4.6869 mL | |
| 10 mM | 0.2343 mL | 1.1717 mL | 2.3435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
